Roche Holding AG Price to Book Ratio 2010-2024 | RHHBY

Historical price to book ratio values for Roche Holding AG (RHHBY) over the last 10 years. The current price to book ratio for Roche Holding AG as of April 25, 2025 is 6.04.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Roche Holding AG Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2025-04-24 39.75 0.00
2024-12-31 33.76 0.00
2023-12-31 33.64 0.00
2023-06-30 35.47 0.00
2022-12-31 35.05 0.00
2022-06-30 37.34 0.00
2021-12-31 45.05 0.00
2021-06-30 40.96 0.00
2020-12-31 37.06 0.00
2020-06-30 36.67 0.00
2019-12-31 33.32 0.00
2019-06-30 28.77 0.00
2018-12-31 24.67 0.00
2018-06-30 21.93 0.00
2017-12-31 24.15 0.00
2017-06-30 24.32 0.00
2016-12-31 21.13 0.00
2016-06-30 24.41 0.00
2015-12-31 24.72 0.00
2015-06-30 25.15 0.00
2014-12-31 23.61 0.00
2014-06-30 25.91 0.00
2013-12-31 23.66 0.00
2013-06-30 20.85 0.00
2012-12-31 16.42 0.00
2012-06-30 14.06 0.00
2011-12-31 13.25 0.00
2011-06-30 13.07 0.00
2010-12-31 10.89 0.00
2010-06-30 10.19 0.00
2009-12-31 12.14 0.00
2009-06-30 9.81 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.102B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Novo Nordisk (NVO) Denmark $260.636B 17.65
Novartis AG (NVS) Switzerland $234.183B 14.19
Merck (MRK) United States $196.697B 10.21
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Bayer (BAYRY) Germany $23.657B 4.39
Innoviva (INVA) United States $1.145B 10.56